Companies C4 Therapeutics, Inc.
C4 Therapeutics (CCCC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me C4 Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers35th pct.Of 20 peer CEOs
CEO pay, last three years
- $3,790,099FY2023
- $5,239,784FY2024
- $2,940,975FY2025
CEO total pay was $2,940,975 in fiscal 2025, down from $5,239,784 in fiscal 2024.
FY2025: salary $694,925 · bonus $100,000 · stock awards $710,730 · option awards $848,007
Executives and directors
Andrew Hirsch · CEOKendra Adams · CFOLeonard Reyno · Chief Medical OfficerBruce Downey · Former director (through FY2025)Donna Grogan · Independent DirectorKenneth C. Anderson · Independent DirectorLaura Bessen · Independent DirectorOwen P. Hughes Jr · Independent DirectorRonald Harold Wilfred Cooper · Chair of the BoardStephen Fawell · Independent DirectorStephen Hoerter · Independent DirectorUtpal Koppikar · Independent Director
Frequently asked questions
Who was the highest-paid executive at C4 Therapeutics, Inc. in fiscal 2025?
As disclosed, Andrew Hirsch (President and Chief Executive Officer) was the highest-paid executive at C4 Therapeutics, Inc. in fiscal 2025, with total compensation of $2,940,975.
How does C4 Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Andrew Hirsch's total compensation ranked at the 35th percentile of C4 Therapeutics, Inc.'s disclosed peer group.
How did shareholders vote on C4 Therapeutics, Inc.'s executive compensation?
As disclosed, 98.09% of shareholders supported C4 Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does C4 Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, C4 Therapeutics, Inc. reported total board compensation of $469,621 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Hirsch | $694,925 | $100,000 | $710,730 | $848,007 | $573,313 | $0 | $14,000 | $2,940,975 |
| President and Chief Executive Officer | ||||||||
| Leonard Reyno | 597,740 | 100,000 | 276,978 | 330,300 | 322,780 | 0 | 14,000 | 1,641,798 |
| Chief Medical Officer | ||||||||
| Kendra Adams | 506,825 | 75,000 | 276,978 | 330,300 | 273,686 | 0 | 14,000 | 1,476,789 |
| Chief Financial Officer and Head of Corporate Affairs | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Andrew Hirsch | $2,940,975 | $5,239,784 | $3,790,099 | ↓ −2,298,809 |
| Leonard Reyno | 1,641,798 | 2,314,100 | 1,674,727 | ↓ −672,302 |
| Kendra Adams | 1,476,789 | 2,197,489 | — | ↓ −720,700 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation program is designed to align executive interests with the drivers of growth and stockholder returns by supporting the Company’s achievement of its primary business goals and creating long-term stockholder value. It focuses on incenting executives to take actions that create long-term stockholder value, rewarding the achievement of short-term corporate goals, and attracting and retaining highly qualified executive officers.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kendra Adams | Option | — | — | — | — | — | $330,300 |
| Leonard Reyno | RSU | — | — | — | — | — | 276,978 |
| Andrew Hirsch | Option | — | — | — | — | — | 848,007 |
| Kendra Adams | RSU | — | — | — | — | — | 276,978 |
| Leonard Reyno | Option | — | — | — | — | — | 330,300 |
| Andrew Hirsch | RSU | — | — | — | — | — | 710,730 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kendra Adams | $276,978 | $0 | $330,300 | 0.0% |
| Leonard Reyno | 276,978 | 0 | 330,300 | 0.0% |
| Andrew Hirsch | 710,730 | 0 | 848,007 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kendra Adams | Option | 2,813 | 19 | — |
| Kendra Adams | RSU | 7,500 | — | 14,325 |
| Kendra Adams | RSU | 12,500 | — | 23,875 |
| Kendra Adams | Option | 23,438 | 5.67 | — |
| Kendra Adams | RSU | 27,525 | — | 52,573 |
| Leonard Reyno | RSU | 27,525 | — | 52,573 |
| Leonard Reyno | RSU | 30,650 | — | 58,542 |
| Andrew Hirsch | RSU | 40,800 | — | 77,928 |
| Kendra Adams | Option | 48,563 | 2.15 | — |
| Andrew Hirsch | RSU | 77,550 | — | 148,121 |
| Kendra Adams | RSU | 87,100 | — | 166,361 |
| Leonard Reyno | RSU | 87,100 | — | 166,361 |
| Kendra Adams | Option | 92,982 | 7.31 | — |
| Leonard Reyno | Option | 92,982 | 7.31 | — |
| Kendra Adams | Option | 103,392 | 3.18 | — |
| Leonard Reyno | Option | 103,392 | 3.18 | — |
| Andrew Hirsch | Option | 114,750 | 5.77 | — |
| Leonard Reyno | Option | 120,750 | 3.5 | — |
| Andrew Hirsch | RSU | 223,500 | — | 426,885 |
| Andrew Hirsch | Option | 261,844 | 7.31 | — |
| Andrew Hirsch | Option | 265,446 | 3.18 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ronald Harold Wilfred CooperIndependent · Nominating and Corporate Governance (Chair) | $79,500 | $0 | $39,749 | — | $0 | $119,249 |
| Utpal KoppikarIndependent · Audit (Chair) · Organization, Leadership and Compensation | 60,750 | 0 | 39,749 | — | 0 | 100,499 |
| Donna GroganIndependent · Organization, Leadership and Compensation · Science and Technology (Chair) · Partial-year service | 57,250 | 0 | 39,749 | — | 0 | 96,999 |
| Stephen HoerterIndependent · Audit · Organization, Leadership and Compensation (Chair) | 50,563 | 0 | 39,749 | — | 0 | 90,312 |
| Laura BessenIndependent · Nominating and Corporate Governance · Science and Technology · Partial-year service | 50,500 | 0 | 39,749 | — | 0 | 90,249 |
| Owen P. Hughes JrIndependent · Audit · Nominating and Corporate Governance | 50,208 | 0 | 39,749 | — | — | 89,958 |
| Kenneth C. AndersonIndependent · Science and Technology · Partial-year service | 45,750 | 0 | 39,749 | — | 0 | 85,499 |
| Stephen FawellIndependent · Science and Technology | 45,750 | 0 | 39,749 | — | 0 | 85,499 |
| Bruce DowneyIndependent | 29,350 | 0 | 0 | — | 0 | 29,350 |
| Andrew J. HirschEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $469,621 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $469,621 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names C4 Therapeutics as a peer
Companies that benchmark against CCCC
6 companies name CCCC as a compensation peer
The list of companies that name CCCC as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
PRLD Prelude Therapeutics IncorporatedTNGX Tango Therapeutics, Inc.NKTX Nkarta, Inc.ARVN Arvinas, Inc.BDTX Black Diamond Therapeutics, Inc.RLAY Relay Therapeutics, Inc.ACET Adicet Bio, Inc.IGMS IGM Biosciences, Inc.CGEM Cullinan Therapeutics, Inc.EDIT Editas Medicine, Inc.FHTX Foghorn Therapeutics Inc.FULC Fulcrum Therapeutics, Inc.ITOS iTeos Therapeutics, Inc.KYMR Kymera Therapeutics, Inc.LYEL Lyell Immunopharma, Inc.GLUE Monte Rosa Therapeutics, Inc.NRIX Nurix Therapeutics, Inc.ORIC ORIC Pharmaceuticals, Inc.PSTX Poseida Therapeutics, Inc.STRO Sutro Biopharma, Inc.
Peer reciprocity
The companies C4 Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | $693,000 | $0 | $7,318,859 | $519,750 | $8,545,609 |
| 2 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 3 | Nurix Therapeutics, Inc. | 2025 | Arthur Sands | 674,584 | 0 | 5,166,196 | 510,000 | 6,374,138 |
| 4 | iTeos Therapeutics, Inc. | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 5 | Oric Pharmaceuticals, Inc. | 2025 | Jacob Chacko | 657,500 | 826,000 | 3,634,560 | 434,000 | 5,567,164 |
| 6 | Cullinan Therapeutics, Inc. | 2025 | Nadim Ahmed | 698,476 | 1,697,400 | 2,234,340 | 419,086 | 5,100,006 |
| 7 | Monte Rosa Therapeutics, Inc. | 2025 | Markus Warmuth | 650,000 | 910,080 | 3,043,648 | 429,000 | 5,032,728 |
| 8 | Relay Therapeutics, Inc. | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 9 | Lyell Immunopharma, Inc. | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 10 | Poseida Therapeutics, Inc. | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 11 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 12 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 13 | Nkarta, Inc. | 2025 | Paul Hastings | 674,384 | 236,250 | 1,711,957 | 344,947 | 2,978,038 |
| 14 | C4 Therapeutics, Inc. | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 15 | Tango Therapeutics, Inc. | 2025 | Barbara Weber | 697,950 | 308,096 | 1,275,328 | 524,250 | 2,823,992 |
| 16 | Foghorn Therapeutics Inc. | 2025 | Adrian Gottschalk | 638,000 | 0 | 1,334,037 | 385,990 | 2,361,027 |
| 17 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 18 | Black Diamond Therapeutics, Inc. | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 19 | Sutro Biopharma, Inc. | 2025 | William Newell | 239,693 | 0 | 0 | 0 | 1,671,311 |
| 20 | Adicet Bio, Inc. | 2025 | Chen Schor | 646,294 | 0 | 512,079 | 284,592 | 1,465,747 |
| 21 | Prelude Therapeutics Incorporated | 2025 | Krishna Vaddi | 615,441 | 0 | 412,744 | 309,465 | 1,348,000 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| C4 Therapeutics, Inc. | 120% | not disclosed | not disclosed | Pearl Meyer |
| Adicet Bio, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Black Diamond Therapeutics, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| Cullinan Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Compensia (through June 2025); Pay Governance (since June 2025) |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Foghorn Therapeutics Inc. | not disclosed | Options 100 | not disclosed | Pay Governance, LLC |
| Fulcrum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| iTeos Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Lyell Immunopharma, Inc. | 100% | not disclosed | No | Alpine |
| Monte Rosa Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, an Aon Hewitt Company |
| Nkarta, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Nurix Therapeutics, Inc. | not disclosed | Option 60 · RSU 40 | not disclosed | Aon plc |
| Oric Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Poseida Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Prelude Therapeutics Incorporated | not disclosed | Option 100 | not disclosed | Compensia |
| Relay Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon |
| Sutro Biopharma, Inc. | 115% | Options 59 · RSU 41 | not disclosed | FW Cook |
| Tango Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-24 | 54,935,574 | 1,070,926 | 38,870 | 98.09% | Passed |
| 2025 | 2025-06-18 | 48,851,725 | 889,711 | 51,568 | 98.21% | Passed |
| 2024 | 2024-06-20 | 34,500,552 | 11,936,841 | 121,392 | 74.29% | Passed |
| 2023 | 2023-06-15 | 32,361,188 | 609,507 | 1,991,285 | 98.15% | Passed |
| 2022 | 2022-06-22 | 29,207,646 | 262,241 | 564,306 | 99.11% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-24 | 98.09%a |
| 2025 | 2025-06-18 | 98.21%b |
| 2024 | 2024-06-20 | 74.29%c |
a. Approved under the standard stated in the filing — “Abstentions and "broker non-votes" will have no effect on the outcome of Proposal No.”.
b. Approved under the standard stated in the filing — “Abstentions and "broker non-votes" will have no effect on the outcome of Proposal No.”.
c. Approved under the standard stated in the filing — “Abstentions also will have no effect on the ratification of the non-binding, advisory vote to approve the compensation of our named executive officers (Proposal No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-06-01 | — | 1,070 | — | — | 1 insider, 1 accrual row | ||
| Kenneth C. Anderson | Director | 2026-06-01 | A | 1,070 | 2 | 2,258 | Common | Form 4 ↗ |
| Stephen Hoerter | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Fawell | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Bessen | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald Harold Wilfred Cooper | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donna Grogan | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth C. Anderson | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Owen P. Hughes Jr | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Utpal Koppikar | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donna Grogan | Director | 2026-07-01 | A | 3,341 | 4 | 14,500 | Common | Form 4 ↗ |
| Kenneth C. Anderson | Director | 2026-07-01 | A | 2,650 | 4 | 11,501 | Common | Form 4 ↗ |
| Leonard Reyno | Chief Medical Officer | 2026-07-10 | D | 7,397 | 4 | 30,032 | Common | Form 4 ↗ |
| Leonard Reyno | Chief Medical Officer | 2026-07-10 | A | 15,325 | 0 | 0 | Common | Form 4 ↗ |
| Kendra Adams | Chief Financial Officer | 2026-09-18 | A | 6,250 | 0 | 0 | Common | Form 4 ↗ |
| Kendra Adams | Chief Financial Officer | 2026-09-18 | D | 2,775 | 3 | 9,407 | Common | Form 4 ↗ |
| Kenneth C. Anderson | Director | 2026-10-01 | A | 3,662 | 3 | 11,499 | Common | Form 4 ↗ |
| Donna Grogan | Director | 2026-10-01 | A | 4,618 | 3 | 14,501 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 18 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Kenneth C. Anderson | Director | 2026-06-01 | D | 1,070 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth C. Anderson | Director | 2026-06-01 | A | 1,070 | 2 | 2,258 | Common | Form 4 ↗ |
| Stephen Hoerter | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Fawell | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Bessen | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald Harold Wilfred Cooper | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donna Grogan | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth C. Anderson | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Owen P. Hughes Jr | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Utpal Koppikar | Director | 2026-06-24 | A | 62,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donna Grogan | Director | 2026-07-01 | A | 3,341 | 4 | 14,500 | Common | Form 4 ↗ |
| Kenneth C. Anderson | Director | 2026-07-01 | A | 2,650 | 4 | 11,501 | Common | Form 4 ↗ |
| Leonard Reyno | Chief Medical Officer | 2026-07-10 | D | 7,397 | 4 | 30,032 | Common | Form 4 ↗ |
| Leonard Reyno | Chief Medical Officer | 2026-07-10 | A | 15,325 | 0 | 0 | Common | Form 4 ↗ |
| Kendra Adams | Chief Financial Officer | 2026-09-18 | A | 6,250 | 0 | 0 | Common | Form 4 ↗ |
| Kendra Adams | Chief Financial Officer | 2026-09-18 | D | 2,775 | 3 | 9,407 | Common | Form 4 ↗ |
| Kenneth C. Anderson | Director | 2026-10-01 | A | 3,662 | 3 | 11,499 | Common | Form 4 ↗ |
| Donna Grogan | Director | 2026-10-01 | A | 4,618 | 3 | 14,501 | Common | Form 4 ↗ |
Sources (66 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Andrew Hirsch. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · page 38. As printed: 2,940,975. View filing ↗
- Section 01, Leonard Reyno. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,641,798. View filing ↗
- Section 01, Kendra Adams. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,476,789. View filing ↗
- Section 03, Kendra Adams Option. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Leonard Reyno RSU. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Hirsch Option. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kendra Adams RSU. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Leonard Reyno Option. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Hirsch RSU. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-02-26. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Ronald Harold Wilfred Cooper. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 119,249. View filing ↗
- Section 08, Utpal Koppikar. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 100,499. View filing ↗
- Section 08, Donna Grogan. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 96,999. View filing ↗
- Section 08, Stephen Hoerter. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 90,312. View filing ↗
- Section 08, Laura Bessen. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 90,249. View filing ↗
- Section 08, Owen P. Hughes Jr. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 89,958. View filing ↗
- Section 08, Kenneth C. Anderson. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 85,499. View filing ↗
- Section 08, Stephen Fawell. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 85,499. View filing ↗
- Section 08, Bruce Downey. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 29,350. View filing ↗
- Section 08, Andrew J. Hirsch. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Kenneth C. Anderson 2026-06-01. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth C. Anderson 2026-06-01. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Hoerter 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Fawell 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Bessen 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ronald Harold Wilfred Cooper 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donna Grogan 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth C. Anderson 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Owen P. Hughes Jr 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Utpal Koppikar 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donna Grogan 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth C. Anderson 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard Reyno 2026-07-10. Form 4, filed 2026-07-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard Reyno 2026-07-10. Form 4, filed 2026-07-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kendra Adams 2026-09-18. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kendra Adams 2026-09-18. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth C. Anderson 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donna Grogan 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-24. Item 5.07 · say-on-pay result. As reported: 98.09% (votes for as printed: 54,935,574). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 98.21% (votes for as printed: 48,851,725). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-21. Item 5.07 · say-on-pay result. As reported: 74.29% (votes for as printed: 34,500,552). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 469,621 + equity 0 + all other 0 = 469,621, summed across the director compensation table rows.
- Kymera Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. View filing ↗
- Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
- Nurix Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Nurix Therapeutics, Inc.'s own proxy. As printed: 6,374,138. View filing ↗
- iTeos Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in iTeos Therapeutics, Inc.'s own proxy. As printed: 6,085,657. View filing ↗
- Oric Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Oric Pharmaceuticals, Inc.'s own proxy. As printed: 5,567,164. View filing ↗
- Cullinan Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cullinan Therapeutics, Inc.'s own proxy. As printed: 5,100,006. View filing ↗
- Monte Rosa Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Monte Rosa Therapeutics, Inc.'s own proxy. As printed: 5,032,728. View filing ↗
- Relay Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. View filing ↗
- Lyell Immunopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. View filing ↗
- Poseida Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. View filing ↗
- Fulcrum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗
- IGM Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. View filing ↗
- Nkarta, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Nkarta, Inc.'s own proxy. As printed: 2,978,038. View filing ↗
- C4 Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in C4 Therapeutics, Inc.'s own proxy. As printed: 2,940,975. View filing ↗
- Tango Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Tango Therapeutics, Inc.'s own proxy. As printed: 2,823,992. View filing ↗
- Foghorn Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Foghorn Therapeutics Inc.'s own proxy. As printed: 2,361,027. View filing ↗
- Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
- Black Diamond Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Black Diamond Therapeutics, Inc.'s own proxy. As printed: 2,234,919. View filing ↗
- Sutro Biopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sutro Biopharma, Inc.'s own proxy. As printed: 1,671,311. View filing ↗
- Adicet Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. View filing ↗
- Prelude Therapeutics Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Prelude Therapeutics Incorporated's own proxy. As printed: 1,348,000. View filing ↗
- Section 10a, Nurix Therapeutics, Inc. reciprocity. DEF 14A. Nurix Therapeutics, Inc. names C4 Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗